Navigation Links
Xencor's XmAb5871 Enters Phase 2a Study for Autoimmune Disease
Date:10/1/2013

ng engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Currently, five antibodies are in clinical development internally and with partners that have been engineered with Xencor's XmAb technology. Xencor's internally-discovered programs include XmAb5871, in Phase 2a for the treatment of Rheumatoid arthritis and lupus, XmAb7195 in preclinical development for the treatment of asthma, and XmAb5574/MOR208 which has been licensed to Morphosys AG and is in Phase 2 clinical trials for the treatment of acute lymphoblastic leukemia and non-Hodgkin lymphoma. Xencor's XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. Xencor partners include Amgen, Merck, Janssen R&D LLC and Boehringer Ingelheim.


'/>"/>
SOURCE Xencor, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Sacom SPA, Leader in the Italian Green Biotechnology Fertilizer Industry, Enters the VedoGreen Financial Network
2. U.S. Blood Centers Pursue an Evolving Role in Cell Therapies
3. Blood Centers of America Experiences Record Growth
4. Verenium Enters Agreement To Be Acquired By BASF
5. CCG Investor Relations Announces Company Presenters for NexGen Life Sciences Virtual Conference
6. Independent Living Centers Play A Vital Role In Helping Students Transition Out Of High School
7. Curemark Enters into Research Collaboration with The Molecular Sciences Institute (VTT/MSI)
8. Gallus BioPharmaceuticals Enters Clinical Supply Agreement with Genzyme for Niemann-Pick Type B Disease
9. Inflamax Research Inc. Enters Strategic Partnership with Northern Air Environmental Technologies Inc.
10. 7 SynCardia Certified Centers Honored Among “Best Children’s Hospitals” for Cardiology and Heart Surgery by U.S. News & World Report
11. VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... and BOSTON , Oct. ... ), a leading global specialty pharmaceutical company, and Rhythm, ... granted an exclusive option to acquire Rhythm,s wholly owned ... a peptide ghrelin agonist, for the treatment of diabetic ... Rhythm has completed a successful Phase 2 trial of ...
(Date:10/22/2014)... Involution Studios , a healthcare software ... infographic, Understanding Ebola . The goal of ... to follow informative tool for anyone wanting to know ... prevention. , "As the news has spread in all ... represents not only a healthcare crisis with global impact, ...
(Date:10/22/2014)... SC (PRWEB) October 22, 2014 ... of its cardiovascular pharmacogenetics menu, which enables healthcare ... outcomes. With PCLS’s evidence-based results, healthcare providers ... and optimize their therapy, while minimizing risks for ... the U.S., according to the FDA [1] more ...
(Date:10/22/2014)... , Oct. 22, 2014 Nuvilex, Inc. ... approximately 400 million people worldwide are living with diabetes, ... people by 2030.  The global market for diabetes treatments ... approximately 330,000 people worldwide died from pancreatic cancer.  Pancreatic ... due to cancer in the United States ...
Breaking Biology Technology:Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2
... Longer-term Phase 2 Switching Study, CRANBURY, ... company developing small-molecule, orally administered,pharmacological chaperones for ... that the Company will present positive results ... (isofagomine tartrate) for Gaucher disease,at the American ...
... on the strangeness of the nanoworld, researchers at the ... University of Maryland-College Park have discovered that materials such ... behave as ductile as gold at the nanoscale. Their ... NIST scientists Pradeep Namboodiri and Doo-In Kim and colleagues ...
... Calif., March 12 ,Exelixis, Inc. (Nasdaq: EXEL ) ... executive officer of Exelixis, will present at the,Cowen and ... / 1:00 p.m.,PT on Monday, March 17, 2008. Dr. ... corporate strategy., The presentation will be webcast and ...
Cached Biology Technology:Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease 2Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease 3Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease 4Nanomaterials show unexpected strength under stress 2
(Date:10/15/2014)... Oct. 15, 2014   Neurotechnology , a ... the availability of the VeriLook Surveillance 3.0 ... provides real-time biometric face identification using live video ... cameras. The new version not only identifies faces ... from objects while they are moving through the ...
(Date:10/14/2014)... house fly genome for the first time, revealing robust ... that thrives in pathogen-rich dung piles and garbage heaps. ... Genome Biology , will increase understanding of house ... adapt to resist insecticides, which could lead to novel ... and transmit more than 100 human and animal diseases, ...
(Date:10/14/2014)... LA JOLLA, CA – October 14, 2014 – Scientists ... $6.6 million from the National Institutes of Health (NIH) ... most prevalent virus-induced hemorrhagic fever disease in Africa. The ... disease and why some patients die, while others survive ... researchers to understand the basic mechanism of how Lassa ...
Breaking Biology News(10 mins):VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 2VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 3House fly genome reveals expanded immune system 2Scripps Research Institute team receives $6.6 million to investigate deadly Lassa virus 2
... anachronism? Or is it a vital part of a ... 2.4 billion more people by the year 2050, the drive ... , But there,s an important downside to this trend, argues ... Montreal, in a paper to be presented Saturday, Feb. 15, ...
... Calif.) When mothers feed their newborns formula in the ... in the second month of life and more likely to ... longer, UC Davis researchers have found. "We are ... hospital can cause problems by reducing how much women breastfeed ...
... Rochelle, NY, February 13, 2014Food spoiling and poisoning caused ... economic problems. The broad scope of antimicrobial approaches to ... and beverages, including a variety of natural and artificial ... in Industrial Biotechnology , a peer-reviewed journal from ...
Cached Biology News:Making biodiverse agriculture part of a food-secure future 2Making biodiverse agriculture part of a food-secure future 3In-hospital formula use deters breastfeeding 2In-hospital formula use deters breastfeeding 3
... Ambion's ActivePro In ... from an E.coli lysate, ... protein as well as ... activity than competing kits. ...
... Mouse Serum • Mouse serum is collected off ... and 8-12 weeks of age. Available Anticoagulants: ... N-06: K2EDTA N-08: Potassium Oxalate ... N-05: ACD N-07: CPD ...
GeneRacer is an advanced RACE (rapid amplification of cDNA ends) technique that improves the efficiency of amplifying full-length 5' and 3' cDNA ends. With the GeneRacer Kit you can:...
One-step, microplate or cuvet, colorimetric, linear detection range 0.6 mM to 100 mM. Procedure: 2 min....
Biology Products: